Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 0.75 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30926644 | 0.88 | MAPT (0.72) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27181232 | 0.88 | MAPT (0.72) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11025715 | 0.88 | POLB (0.78) | TCF4CTNNB1ALDH1A1MAPTMEN1 | |
| SCHEMBL2941161 | 0.88 | CA12 (0.69) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15840563 | 0.87 | MAPT (0.64) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4928453 | 0.87 | TCF4 (0.73) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23093353 | 0.87 | HTR6 (0.66) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2234179 | 0.87 | SMN1; SMN2 (0.81) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21802493 | 0.87 | CYP19A1 (0.69) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16116948 | 0.86 | TCF4 (1.00) | TCF4CTNNB1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469606-B2 | Wnt/b-catenin inhibitors and methods of use | THE GENERAL HOSPITAL CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140288174-A1 | WNT/B-CATENIN INHIBITORS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION | 2014-09-25 | — | — | US | disclosed |
| EP-0729465-B1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6005103-A | TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS | WARNER-LAMBERT COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
| US-5808062-A | AIDS THERAPY | WARNER-LAMBERT COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0729465-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729466-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014013-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014014-A2 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| US-4521422-A | ANTICONVULSANT, ANTIEPILEPTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS | AMERICAN CYANAMID COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0129847-A2 | Aryl and heteroaryl[7-(aryl and heteroaryl)-pyrazolo-[1,5-a]-pyrimidin-3-yl]methanones | AMERICAN CYANAMID COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288174-A1 | WNT/B-CATENIN INHIBITORS AND METHODS OF USE | WNT1, WNT3A, CTNNB1 | TCF4 551/4885CTNNB1 3/4885ALDH1A1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.